Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation

Therapy

Volumn 2, Issue 1, 2005, Pages 95-105

  Cattaneo, Dario ^a   Gaspari, Flavio ^a   Zenoni, Stefania ^a   Baldelli, Sara ^a   Gotti, Eliana ^b   Perna, Annalisa ^b   Perico, Norberto ^a   Remuzzi, Giuseppe ^a  

^a Center for Organ Transplantation   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Cyclosporine; Graft dysfunction; Kidney transplantation; Limited sampling strategy; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DIALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 13444304416     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.1.95     Document Type: Article

References (45)

1. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin. Pharmacol. Ther. 54, 205-218 (1993).
2. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46, 631-644 (1988).
3. Meyer MM, Munar M, Udeaja J, Bennett W. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J. Am. Soc. Nephrol. 4, 1306-1315 (1993).
4. Kasiske B, Heim-Duthoy K, Rao KV, Awni WM. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 46, 716-722 (1988).
5. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-curve. review of current algorithms. Ther. Drug Monit. 23, 100-114 (2001).
6. Foradori AC, Martinez L, Vacarezza A, Elberg L, Loveluck A, Pinto C. Pharmacokinetics of a new galenic formulation of oral cyclosporine A in stable Kidney transplanted patients. Transplant Proc. 26, 2969-2972 (1994).
7. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin. Transplant 12, 243-249 (1998).
8. Grant D, Kneteman N, Tchervenkov J et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection. Transplantation 67, 1133-1137 (1999).
9. Cantarovich M, Barkun JS, Tchrvenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66, 1621-1627 (1998).
10. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical Benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with through levels in stable heart transplant recipients. Transplantation 68, 1839-1842 (1999).
11. Lindholm A. Cyclosporine A. clinical experience and therapeutic drug monitoring. Ther. Drug Monit. 17, 631-637 (1995).
12. Dumont RJ, Ensom MH. Methods for clinical monitoring in transplant patient. Clin. Pharmacokinet. 38, 427-447 (2000).
13. Nankivell BJ, Gruenewald SM, Allen RDM, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 59, 1683-1689 (1995).
14. Perico N, Ruggenenti P, Gaspari F et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54, 56-60 (1992).
15. 2 monitoring, an international consensus statement. Transplantation Suppl. (73), S12-S18 (2002).
16. 2 blood levels in stable renal allograft recipients. Transplant. Proc. 34, 1738-1739 (2002).
17. Keown P, Landsberg D, Halloran P et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation 62, 1744-1752 (1996).
18. Gaspari F, Anedda MF, Signorini O, Remuzzi G, Perico N. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J. Am. Soc. Nephrol. 8, 647-652 (1997).
19. Campbell MJ, Machin D (eds). In: Medical statistics. a common sense approach. Chichester. John Wiley & Sons LTD, NY, USA (1999).
20. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 72, 1024-1032 (2001).
21. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am. J. Transplant. 2, 148-156 (2002).
22. 2 monitoring in pediatric liver transplant recipients. Transplant. Proc. 33, 3094-3095 (2001).
23. Kelles A, Herman J, Tjandra-Maga TB, Van Damme-Lombaerts R. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr. Transplant. 3, 282-287 (1999).
24. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68, 55-62 (1999).
25. Kazangioglu R, Goral S, Shockley SL et al. A systematic examination of estimates of cyclosporine area under the curve in renal transplant recipients. Transplantation 73, 301-302 (2002).
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 356, 307-310 (1986).
27. Kahan BD. Overview. individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic: parameters. Transplantation 40, 457-476 (1985).
28. Kahan BD, Dunn J, Fitts C et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 59, 505-511 (1995).
29. Warrens AN, Waters JB, Salama AD, Lechler RI. Improving the therapeutic monitoring of cyclosporin A. Clin. Transplant. 13, 193-200 (1999).
30. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther. Drug Monit. 24, 479-486 (2002).
31. Keshavamurthy M, Al Ahmadi I, Mohammed Raza S. Single-center study utilizing C2 level as monitoring tool in de novo renal transplant recipients treated with Neoral. Transplant. Proc. 33, 3112-3114 (2001).
32. 2 level monitoring in de novo renal transplant recipients. Transplant. Proc. 33, 3098-3099 (2001).
33. Levy GA, Burra P, Cavallari A et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on two-hour post dose levels (C2). Transplantation 73, 953-959 (2002).
34. Levy GA. Neoral C2 in liver transplant recipients. Transplant. Proc. 33, 3089-3091 (2001).
35. 2) from drug ingestion as the best single indicator of adequate cyclosporine immunosuppression in renal allograft recipients - a four-year follow-up. Transplant. Proc. 34, 556-557 (2002).
36. Halloran PF, Helms L.M, Kung L, Noujamin J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68, 1356-1361 (1999).
37. Sindhi R, LaVia MF, Paulling E et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation 69, 432-436 (2000).
38. 2) of CyA in human renal allograft recipients. Transplant. Proc. 33, 3148-3150 (2001).
39. Nankivell BJ, Fenton-Lee CA, Kuypers DRJ et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 71, 515-523 (2001).
40. Beveridge T, Calne RY. Cyclosporine (Sandimmune) in cadaveric renal transplantation. Ten-year follow-up of a multicenter trial. European Multicentre Trial Group. Transplantation 59, 1568-1570 (1995).
41. Remuzzi G, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int. Suppl. (52), S70-S74 (1995).
42. Weir MR, Traver WM, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibition in patients with chronic allograft nephropathy. Kidney Int. 59, 1567-1573 (2001).
43. Mourad G, Vela C, Ribstein J, Mirman A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 65, 661-667 (1998).
44. Citterio F, Scata MC, Borzi MT, Pozzetto U, Castagneto M. Single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients. Tranplant. Proc. 33, 3133-3136 (2001 ).
45. Di Paolo S, Teutonico A, Schena A et al.. Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients. results at 3 years. Am. J. Kidney Dis. 44, 886-892 (2004).